First quarter 2022 net revenue increased 72% year-over-year to $4.0 million
First quarter 2022 total prescription growth for JATENZO® increased 12% sequentially and increased 75% year-over-year
Read more at globenewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
First quarter 2022 net revenue increased 72% year-over-year to $4.0 million
First quarter 2022 total prescription growth for JATENZO® increased 12% sequentially and increased 75% year-over-year
Read more at globenewswire.com